News & Updates

Etavopivat reduces VOCs in patients with sickle cell disease

29 Jan 2025 by

Once-daily treatment with etavopivat results in lower rates of annualized vaso-occlusive crises (VOCs) in patients with sickle cell disease (SCD) compared with placebo, according to the HIBISCUS trial presented at ASH 2024.

Etavopivat reduces VOCs in patients with sickle cell disease

29 Jan 2025

CKD predicts cardiac, cerebral events risk in patients with chronic coronary syndrome

28 Jan 2025

Among patients with chronic coronary syndrome, those with chronic kidney disease (CKD) at baseline are at increased risk of major adverse cardiac and cerebral events (MACCE), according to data from the REAL‐CAD* study.

CKD predicts cardiac, cerebral events risk in patients with chronic coronary syndrome

28 Jan 2025

Undernutrition impairs measles, tetanus vax responses in children

28 Jan 2025 by

Children who are undernourished may have a compromised immune response to certain vaccines, and this impaired response can contribute to the burden of vaccine-preventable diseases, according to the VHEMBE* South African birth cohort study.

Undernutrition impairs measles, tetanus vax responses in children

28 Jan 2025

PegIFN-α-2a lowers relapse in HBeAg-negative patients after NUC cessation

28 Jan 2025

Switching treatment from nucleo(s)tide analogue (NUC) to pegylated interferon alpha-2a (PegIFN-α-2a) for 48 weeks results in a significant decrease in virological relapse rates as well as higher hepatitis B surface antigen (HBsAg) loss rates when compared with NUC treatment cessation alone in patients with HBeAg-negative chronic hepatitis B, reports a study.

PegIFN-α-2a lowers relapse in HBeAg-negative patients after NUC cessation

28 Jan 2025

Tremelimumab plus durvalumab improves survival in Asians with unresectable HCC

28 Jan 2025 by

A single tremelimumab regular interval durvalumab (STRIDE) provides survival benefits to Asian patients with unresectable hepatocellular carcinoma (HCC), as shown by the results of the HIMALAYA study.

Tremelimumab plus durvalumab improves survival in Asians with unresectable HCC

28 Jan 2025

Baricitinib cuts need for oral steroids in polymyalgia rheumatica

28 Jan 2025

In the treatment of patients with polymyalgia rheumatica, the Janus kinase 1/2 inhibitor baricitinib helps reduce the need to take oral glucocorticoids to have low disease activity while having no new safety signals, according to data from the randomized, double-blind BACHELOR trial.

Baricitinib cuts need for oral steroids in polymyalgia rheumatica

28 Jan 2025

Bimekizumab eases pain, morning stiffness in axSpA patients

27 Jan 2025 by

Treatment with bimekizumab quickly relieves pain and morning stiffness among patients with axial spondyloarthritis (axSpA), as shown in a study. Such improvements persist through week 52.

Bimekizumab eases pain, morning stiffness in axSpA patients

27 Jan 2025

High-dose folic acid use ups risk of malignancy in women with childbirth experience

27 Jan 2025

A recent study suggests that the use of high-dose folic acid may predispose parous women, including those with epilepsy, to cancer.

High-dose folic acid use ups risk of malignancy in women with childbirth experience

27 Jan 2025

Infliximab does not help with chronic low back pain-related disability

26 Jan 2025

In the treatment of patients with moderate-to-severe chronic low back pain, the use of infliximab does not yield meaningful reductions in pain-related disability when compared with placebo, as shown in a study.

Infliximab does not help with chronic low back pain-related disability

26 Jan 2025

No real-world evidence of montelukast link to neuropsychiatric adverse events in kids

25 Jan 2025 by

The use of montelukast in children treated in routine practice does not appear to pose any risks of neuropsychiatric events such as anxiety, depression, and sleep-related disorders, among others.

No real-world evidence of montelukast link to neuropsychiatric adverse events in kids

25 Jan 2025

News & Updates

Filter by Specialty:

Specialty:

Etavopivat reduces VOCs in patients with sickle cell disease

Etavopivat reduces VOCs in patients with sickle cell disease

CKD predicts cardiac, cerebral events risk in patients with chronic coronary syndrome

CKD predicts cardiac, cerebral events risk in patients with chronic coronary syndrome

Undernutrition impairs measles, tetanus vax responses in children

Undernutrition impairs measles, tetanus vax responses in children

PegIFN-α-2a lowers relapse in HBeAg-negative patients after NUC cessation

PegIFN-α-2a lowers relapse in HBeAg-negative patients after NUC cessation

Tremelimumab plus durvalumab improves survival in Asians with unresectable HCC

Tremelimumab plus durvalumab improves survival in Asians with unresectable HCC

Baricitinib cuts need for oral steroids in polymyalgia rheumatica

Baricitinib cuts need for oral steroids in polymyalgia rheumatica

Bimekizumab eases pain, morning stiffness in axSpA patients

Bimekizumab eases pain, morning stiffness in axSpA patients

High-dose folic acid use ups risk of malignancy in women with childbirth experience

High-dose folic acid use ups risk of malignancy in women with childbirth experience

Infliximab does not help with chronic low back pain-related disability

Infliximab does not help with chronic low back pain-related disability

No real-world evidence of montelukast link to neuropsychiatric adverse events in kids

No real-world evidence of montelukast link to neuropsychiatric adverse events in kids